NOVKAN — Novakand Pharma AB Cashflow Statement
0.000.00%
- SEK22.47m
- SEK0.25m
Annual cashflow statement for Novakand Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -46.5 | -45.7 | -52.5 | -64.9 | -46.2 |
| Depreciation | |||||
| Non-Cash Items | 2.61 | -0.386 | 0.692 | 3.01 | 0 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.84 | 1.63 | 3.87 | 6.2 | -12.4 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -46 | -44.1 | -47.6 | -55.7 | -58.5 |
| Other Investing Cash Flow Items | 0 | 0 | 0 | 0 | — |
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | 0 | 0 | 0 | — |
| Financing Cash Flow Items | 2.31 | -0.302 | -0.569 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 89.2 | 95.6 | 36.2 | 6.21 | 59.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 43.2 | 51.5 | -11.4 | -49.5 | 0.67 |